DIA Singapore Annual Meeting 2025

Drug development and healthcare innovation in Asia is being rapidly reshaped by advancements in digital technologies, e.g. Artificial Intelligence (AI),

cloud platforms, changing regulatory guidelines, and innovative clinical trial methodologies. These transformations are accelerating drug development,

streamlining regulatory review processes, and enhancing patient engagement.

To harness the full potential of these emerging opportunities and foster a dynamic and robust regulatory and clinical trial ecosystem, close

collaborations among regulators, academia, patients, and industry are necessary.

\The DIA Singapore Annual Meeting 2025 invites all stakeholders to share and review the evolving healthcare landscape challenges faced and lessons